Halozyme Therapeutics Announces $1.3B Convertible Notes Offering

What Happened

• Halozyme Therapeutics, Inc. filed an 8-K dated September 18, 2026 reporting that it priced an offering of $1.3 billion aggregate principal amount of convertible senior notes due 2033. The company granted the initial purchasers a 13-day option to buy up to an additional $200 million of the notes. The offering is being made only to persons reasonably believed to be "qualified institutional buyers" under Rule 144A. A press release dated September 17, 2026 was attached as Exhibit 99.1.

Key Details

• Aggregate principal amount: $1.3 billion of convertible senior notes due 2033.
• Overallotment option: Initial purchasers may buy up to an additional $200 million within 13 days.
• Sales limitation: Offered and sold only to qualified institutional buyers (Rule 144A).
• Filing date / press release: 8-K filed September 18, 2026; press release dated September 17, 2026.

Why It Matters

• This is a material capital-raising event: the notes add debt to Halozyme's balance sheet and may convert into equity if conversion features are exercised, which can dilute existing shareholders.
• Terms that affect investors (interest rate, conversion rate, conversion mechanics, and intended use of proceeds) were not detailed in this 8-K; investors should watch for further SEC filings and offering documents for full terms.
• The private placement to institutional buyers (Rule 144A) indicates the transaction is targeted at large qualified investors rather than a registered retail offering.